Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.865
+0.1551.78%
Volume:95.91M
Turnover:839.32M
Market Cap:102.14B
PE:22.31
High:8.890
Open:8.580
Low:8.520
Close:8.710
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.83
T/O Rate:0.83%
Dividend:0.34
Dividend Rate:3.81%
EPS(LYR):0.397
ROE:20.90%
ROA:10.70%
PB:2.32
PE(LYR):22.31
PS:2.79

Loading ...

CSPC Pharmaceutical Group's SYS6041 Combination Therapy Phase II Trial for Recurrent Ovarian Cancer Has Officially Launched at the First Center in China

Stock News
·
Jul 31

CSPC Pharma Secures NMPA Clearance to Begin Clinical Trials for Second Recombinant RSV Vaccine

Bulletin Express
·
Jul 31

CSPC Pharma Says China Clears Clinical Trial for RSV Vaccine Candidate SYS 6057

Reuters
·
Jul 31

CSPC Pharmaceutical - Pharma's Recombinant Rsv Vaccine (Sys6057) Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
Jul 31

CSPC Pharma Ramps up Usd/rmb Hedging with FX Swap, Forwards Totaling USD 344 Million

Reuters
·
Jul 30

CSPC Pharmaceutical - Unit Enters FX Swap and FX Forward Contracts with Icbc Since June 16, 2026

THOMSON REUTERS
·
Jul 30

CSPC Pharmaceutical - Zhongqi to Place USD 3.19 Mln Security Deposit for FX Swap Contract

THOMSON REUTERS
·
Jul 30

CSPC Pharmaceutical Starts Phase 2 Trial of Hypertension Drug

MT Newswires Live
·
Jul 30

Movement Alert|CSPC PHARMA Falls 3.2% in Regular Trading, Trading at 8.47 HKD

Market Focus
·
Jul 30

CSPC Pharma Initiates First Chinese Site for Phase II Trial of siRNA Hypertension Therapy SYH2062

Bulletin Express
·
Jul 29

CSPC PHARMA: FDA Clears Registrational Trial of Nectin-4 ADC CRB-701 for Second-Line Oropharyngeal Cancer

Bulletin Express
·
Jul 29

CSPC Pharma's CRB-701 (SYS 6002) Gets FDA Nod for Phase 2 Trial in Oropharyngeal Cancer

Stock News
·
Jul 29

CSPC Says FDA Clears Crb-701 Pivotal Trial in Second-line Oropharyngeal Cancer

Reuters
·
Jul 29

CSPC Pharmaceutical - Crb-701 Receives FDA Clearance for Registrational Trial in Second-Line Oropharyngeal Cancer

THOMSON REUTERS
·
Jul 29

CSPC Pharmaceutical Group Stock Rallies 3.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 29

Movement Alert|CSPC PHARMA Rises 3.06% in Regular Trading, Mid-Term Profit Alert and Multiple Pipeline Catalysts Continue to Ferment

Market Focus
·
Jul 29

Citi Reaffirms Buy Rating on CSPC Pharma, Sets Price Target at HK$11.50

Deep News
·
Jul 29

Citi: CSPC Pharma's (01093) Interim Profit Alert Far Exceeds Expectations, 'Buy' Rating Reaffirmed

Stock News
·
Jul 28

China's CSPC Pharmaceutical Rises on Robust H1 Earnings Forecast

Reuters
·
Jul 28

CSPC Pharma's Depression Drug Meets Primary Endpoint in Phase 3 Trial

MT Newswires Live
·
Jul 28